首页> 外文OA文献 >Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine
【2h】

Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine

机译:间充质干细胞介导的癌症治疗:个性化药物的双重目标策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer remains one of the leading causes of mortality and morbidity throughout the world. To a significant extent, current conventional cancer therapies are symptomatic and passive in nature. The major obstacle to the development of effective cancer therapy is believed to be the absence of sufficient specificity. Since the discovery of the tumor-oriented homing capacity of mesenchymal stem cells (MSCs), the application of specific anticancer gene-engineered MSCs has held great potential for cancer therapies. The dual-targeted strategy is based on MSCs’ capacity of tumor-directed migration and incorporation and in situ expression of tumor-specific anticancer genes. With the aim of translating bench work into meaningful clinical applications, we describe the tumor tropism of MSCs and their use as therapeutic vehicles, the dual-targeted anticancer potential of engineered MSCs and a putative personalized strategy with anticancer gene-engineered MSCs.
机译:癌症仍然是全世界死亡率和发病率的主要原因之一。在很大程度上,当前的常规癌症疗法本质上是对症的和被动的。人们认为,开发有效的癌症治疗方法的主要障碍是缺乏足够的特异性。自发现间充质干细胞(MSCs)定向于肿瘤的归巢能力以来,特异性抗癌基因改造的MSCs的应用在癌症治疗方面具有巨大潜力。双重靶向策略是基于MSCs定向转移和整合肿瘤特异性抗癌基因并在原位表达的能力。为了将基础工作转化为有意义的临床应用,我们描述了MSC的肿瘤向性及其作为治疗载体的用途,工程MSC的双重靶向抗癌潜力以及采用抗癌基因工程MSC的推定个性化策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号